Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$137178.0.

  • InMed Pharmaceuticals' Cash from Financing Activities fell 11636.5% to -$137178.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $11.0 million, marking a year-over-year increase of 83100.0%. This contributed to the annual value of $12.3 million for FY2025, which is 16365.79% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Cash from Financing Activities stood at -$137178.0 for Q3 2025, which was down 11636.5% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Cash from Financing Activities registered a high of $10.9 million during Q3 2021, and its lowest value of -$836144.0 during Q4 2021.
  • In the last 5 years, InMed Pharmaceuticals' Cash from Financing Activities had a median value of $838239.0 in 2024 and averaged $2.9 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Cash from Financing Activities crashed by 11730.69% in 2023, and later skyrocketed by 464453125.0% in 2025.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Cash from Financing Activities stood at -$836144.0 in 2021, then skyrocketed by 735.69% to $5.3 million in 2022, then crashed by 101.2% to -$63697.0 in 2023, then surged by 631.46% to $338521.0 in 2024, then tumbled by 140.52% to -$137178.0 in 2025.
  • Its Cash from Financing Activities stands at -$137178.0 for Q3 2025, versus $8.2 million for Q2 2025 and $2.9 million for Q1 2025.